ERBB2 and breast carcinoma: Recommendations for adjuvant treatment in the UK changed over the course of recruitment, with taxanes being recommended for node-positive disease from 2006 and adjuvant trastuzumab for HER2-positive breast cancer routinely available only from 2006.